Oxford BioDynamics Management
Management criteria checks 3/4
Oxford BioDynamics' CEO is Jon Anthony Burrows, appointed in Mar 2020, has a tenure of 4.75 years. total yearly compensation is £606.00K, comprised of 55.4% salary and 44.6% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth $31.04K. The average tenure of the management team and the board of directors is 5.1 years and 5.7 years respectively.
Key information
Jon Anthony Burrows
Chief executive officer
UK£606.0k
Total compensation
| CEO salary percentage | 55.4% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.7% |
| Management average tenure | 5.1yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -UK£11m |
| Dec 31 2023 | n/a | n/a | -UK£11m |
| Sep 30 2023 | UK£606k | UK£336k | -UK£11m |
| Jun 30 2023 | n/a | n/a | -UK£10m |
| Mar 31 2023 | n/a | n/a | -UK£8m |
| Dec 31 2022 | n/a | n/a | -UK£7m |
| Sep 30 2022 | UK£521k | UK£302k | -UK£7m |
| Jun 30 2022 | n/a | n/a | -UK£7m |
| Mar 31 2022 | n/a | n/a | -UK£6m |
| Dec 31 2021 | n/a | n/a | -UK£7m |
| Sep 30 2021 | UK£463k | UK£267k | -UK£7m |
| Jun 30 2021 | n/a | n/a | -UK£6m |
| Mar 31 2021 | n/a | n/a | -UK£5m |
| Dec 31 2020 | n/a | n/a | -UK£5m |
| Sep 30 2020 | UK£384k | UK£149k | -UK£4m |
Compensation vs Market: Jon Anthony's total compensation ($USD762.01K) is about average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Jon Anthony's compensation has increased whilst the company is unprofitable.
CEO
Jon Anthony Burrows (62 yo)
4.8yrs
Tenure
UK£606,000
Compensation
Dr. Jon Anthony Joseph Burrows, B.Sc. (Hons), M.Sc. & Ph D., serves as the Chief Executive Officer and Executive Director at Oxford BioDynamics Plc since March 23, 2020. He has been President of Contract S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4.8yrs | UK£606.00k | 0.67% $ 31.0k | |
| CFO & Executive Director | 7.3yrs | UK£239.00k | 0.27% $ 12.8k | |
| Chief Scientific Officer & Executive Director | no data | UK£276.00k | 2.32% $ 108.1k | |
| Chief Operating Officer | no data | no data | 0.32% $ 15.1k | |
| Senior Vice President of Marketing | no data | no data | 0.024% $ 1.1k | |
| Senior Vice President of Business & Corporate Development | 1.1yrs | no data | no data | |
| Chief Data Officer | 5.5yrs | no data | 0.17% $ 7.8k | |
| Company Secretary | no data | no data | no data |
5.1yrs
Average Tenure
62yo
Average Age
Experienced Management: OXBO.F's management team is seasoned and experienced (5.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4.8yrs | UK£606.00k | 0.67% $ 31.0k | |
| CFO & Executive Director | 7.3yrs | UK£239.00k | 0.27% $ 12.8k | |
| Chief Scientific Officer & Executive Director | 17.5yrs | UK£276.00k | 2.32% $ 108.1k | |
| Independent Non-Executive Director | 5.7yrs | UK£45.00k | 0.032% $ 1.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | 8.2yrs | UK£1.00 | 0.091% $ 4.2k | |
| Member of Scientific Advisory Board | 5.2yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Chairman | 4yrs | UK£85.00k | 0.47% $ 22.1k |
5.7yrs
Average Tenure
62yo
Average Age
Experienced Board: OXBO.F's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 10:52 |
| End of Day Share Price | 2024/12/09 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oxford BioDynamics Plc is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tara Raveendran | Shore Capital Group Ltd |
| null null | Stifel, Equities Research |
| Christian Glennie | Stifel, Equities Research |